Arecor and GSK collaborate to advance new vaccines

Published: 16-Jun-2011
Research & Development Finance Pharmaceutical

Agree to combine Arecor\'s formulation technologies with GSK\'s vaccines


Cambridge, UK-based biotech business Arecor has joined forces with pharmaceutical giant GlaxoSmithKline to develop advanced formulations of vaccines that will combine Arecor's Arestat formulation technologies with GSK's proprietary vaccines.

Arecor will receive unspecified payments on relevant development milestones and royalties on sales.

Tom Saylor, chief executive of Arecor, said: ‘The relationship with GSK offers Arecor the potential to apply its broad-ranging expertise in biomolecule stabilisation to specific projects with GSK.’

Arecor was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into stabilisation of biologics.

Arestat is a patented set of tools for stabilisation, which address the main pathways of degradation.

  • Companies:
  • GlaxoSmithKline
  • Arecor
See more

You may also like

Ingredients

Inhibrx milestone triggers payment to Arecor under license agreement

Read more
Under the terms of the license agreement, Arecor received an initial upfront payment from Inhibrx and is entitled to further payments on the achievement of certain development, regulatory and commercial milestones along with annual Technology Access Fees post commercialisation

Trending Articles

  1. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  3. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  4. Dickson achieves ISO 14001 certification ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
  5. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

Inhibrx milestone triggers payment to Arecor under license agreement

Under the terms of the license agreement, Arecor received an initial upfront payment from Inhibrx and is entitled to further payments on the achievement of certain development, regulatory and commercial milestones along with annual Technology Access Fees post commercialisation
Manufacturing

GSK and Pistoia Alliance announce laboratory tech to improve reproducibility

Founded by Pistoia Alliance and now implemented at GSK, the Methods Hub is a digital tool that enables the instant transfer and overlaying of analytical methods
Manufacturing

Wood wins significant $50m US Life Sciences project with GSK

Wood’s three-year contract will support GSK’s production of innovative specialty medicines for the US and globally as part of GSK’s plan to develop the site
Manufacturing

Tickets now on sale for 2023 Manufacturing Chemist Live

Super early bird tickets are now on sale for the annual conference due to take place in Birmingham on 24 – 25 May 2023
Ingredients

Therapeutic: bepirovirsen for chronic hepatitis B

The hepatitis B virus causes both acute and chronic disease. Chronic hepatitis B can progress to complications including cirrhosis and liver cancer
Finance

Sareum notes completion of Sierra Oncology’s acquisition by GSK

Sareum Holdings, the specialist drug development company, notes that GSK has completed its acquisition of Sierra Oncology, the licence holder for SRA737 (a novel Chk1 inhibitor), for $1.9 billion in cash
Research & Development

Pfizer joins drug target identification consortium

Open Targets works pre-competitively, aiming to bridge the gap between pharma companies and not-for-profit research bodies
Subscribe now